These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 18625451)

  • 1. beta-Secretase as a therapeutic target for Alzheimer's disease.
    Ghosh AK; Gemma S; Tang J
    Neurotherapeutics; 2008 Jul; 5(3):399-408. PubMed ID: 18625451
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Memapsin 2 (beta-secretase) inhibitor drug, between fantasy and reality.
    Ghosh AK; Bilcer G; Hong L; Koelsch G; Tang J
    Curr Alzheimer Res; 2007 Sep; 4(4):418-22. PubMed ID: 17908045
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BACE1 (β-secretase) inhibitors for the treatment of Alzheimer's disease.
    Ghosh AK; Osswald HL
    Chem Soc Rev; 2014 Oct; 43(19):6765-813. PubMed ID: 24691405
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Developing β-secretase inhibitors for treatment of Alzheimer's disease.
    Ghosh AK; Brindisi M; Tang J
    J Neurochem; 2012 Jan; 120 Suppl 1(Suppl 1):71-83. PubMed ID: 22122681
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Memapsin 2 (beta-secretase) inhibitors: drug development.
    Ghosh AK; Kumaragurubaran N; Hong L; Koelsh G; Tang J
    Curr Alzheimer Res; 2008 Apr; 5(2):121-31. PubMed ID: 18393797
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gamma-secretase modulation and its promise for Alzheimer's disease: a rationale for drug discovery.
    Beher D
    Curr Top Med Chem; 2008; 8(1):34-7. PubMed ID: 18220930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospects of β-Secretase Inhibitors for the Treatment of Alzheimer's Disease.
    Ghosh AK; Tang J
    ChemMedChem; 2015 Sep; 10(9):1463-6. PubMed ID: 26140607
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The cysteine protease inhibitor, E64d, reduces brain amyloid-β and improves memory deficits in Alzheimer's disease animal models by inhibiting cathepsin B, but not BACE1, β-secretase activity.
    Hook G; Hook V; Kindy M
    J Alzheimers Dis; 2011; 26(2):387-408. PubMed ID: 21613740
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting the β secretase BACE1 for Alzheimer's disease therapy.
    Yan R; Vassar R
    Lancet Neurol; 2014 Mar; 13(3):319-29. PubMed ID: 24556009
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BACE1 inhibitors: Current status and future directions in treating Alzheimer's disease.
    Moussa-Pacha NM; Abdin SM; Omar HA; Alniss H; Al-Tel TH
    Med Res Rev; 2020 Jan; 40(1):339-384. PubMed ID: 31347728
    [TBL] [Abstract][Full Text] [Related]  

  • 11. γ-Secretase as a target for Alzheimer's disease.
    Wolfe MS
    Adv Pharmacol; 2012; 64():127-53. PubMed ID: 22840746
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Study of memapsin 2 (beta-secretase) and strategy of inhibitor design.
    Tang J; Ghosh AK; Hong L; Koelsch G; Turner RT; Chang W
    J Mol Neurosci; 2003; 20(3):299-304. PubMed ID: 14501012
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances in the identification of γ-secretase inhibitors for the treatment of Alzheimer's disease.
    D'Onofrio G; Panza F; Frisardi V; Solfrizzi V; Imbimbo BP; Paroni G; Cascavilla L; Seripa D; Pilotto A
    Expert Opin Drug Discov; 2012 Jan; 7(1):19-37. PubMed ID: 22468891
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of BACE1 for therapeutic use in Alzheimer's disease.
    Luo X; Yan R
    Int J Clin Exp Pathol; 2010 Jul; 3(6):618-28. PubMed ID: 20661410
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disease-modifying approach to the treatment of Alzheimer's disease: from alpha-secretase activators to gamma-secretase inhibitors and modulators.
    Panza F; Solfrizzi V; Frisardi V; Capurso C; D'Introno A; Colacicco AM; Vendemiale G; Capurso A; Imbimbo BP
    Drugs Aging; 2009; 26(7):537-55. PubMed ID: 19655822
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BACE1 as a therapeutic target in Alzheimer's disease: rationale and current status.
    Evin G; Hince C
    Drugs Aging; 2013 Oct; 30(10):755-64. PubMed ID: 23842796
    [TBL] [Abstract][Full Text] [Related]  

  • 17. gamma-Secretase as a therapeutic target in Alzheimer's disease.
    Guardia-Laguarta C; Pera M; Lleó A
    Curr Drug Targets; 2010 Apr; 11(4):506-17. PubMed ID: 20015011
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent developments of structure based beta-secretase inhibitors for Alzheimer's disease.
    Ghosh AK; Kumaragurubaran N; Tang J
    Curr Top Med Chem; 2005; 5(16):1609-22. PubMed ID: 16375745
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic potential of gamma-secretase inhibitors and modulators.
    Imbimbo BP
    Curr Top Med Chem; 2008; 8(1):54-61. PubMed ID: 18220933
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The structural evolution of β-secretase inhibitors: a focus on the development of small-molecule inhibitors.
    Butini S; Brogi S; Novellino E; Campiani G; Ghosh AK; Brindisi M; Gemma S
    Curr Top Med Chem; 2013; 13(15):1787-807. PubMed ID: 23931442
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.